Complete Economic Evaluation of Nintedanib (Vargatef®) Plus Docetaxel as a Second-Line Treatment in Patients with Non-Small Cell Lung Cancer in Mexico
May 1, 2016, 00:00
10.1016/j.jval.2016.03.1593
https://www.valueinhealthjournal.com/article/S1098-3015(16)01661-2/fulltext
Title :
Complete Economic Evaluation of Nintedanib (Vargatef®) Plus Docetaxel as a Second-Line Treatment in Patients with Non-Small Cell Lung Cancer in Mexico
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01661-2&doi=10.1016/j.jval.2016.03.1593
First page :
A150
Section Title :
Cancer - Cost Studies
Open access? :
No
Section Order :
315